Lifeloc Q3 revenue rises 12% as SpinDetect drug analyzer launch slips to Q4 2027
The US breath alcohol specialist narrowed its quarterly loss and delayed the limited launch of its oral-fluid THC analyzer by three quarters, citing a shift in engineering focus and capital access.
Lifeloc Technologies reported net revenue of $2.522 million for the third quarter of 2026, the quarter ended 30 September, up 12% on the same period a year earlier. Gross margin was 43%, and the net loss narrowed to $85,000.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): Lifeloc Technologies, Inc ↗
Article written by VigiEye from the official source (Lifeloc Technologies, Inc). Claims are the company's own. AI-assisted; check the source before acting.